Japanese BAY86-9766 Monotherapy Phase I Study

Inclusion Criteria: * Japanese patients, who are at least 18 years of age at the first screening examination/ visit, with advanced or refractory solid tumors not amenable to standard therapy. * Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the central nervous system (CNS) * At least one measurable lesion or evaluable disease according to response evaluation criteria in solid tumors (RECIST) version 1.1 * Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1 * Life expectancy of at least 12 weeks Exclusion Criteria: * Use of any anti-cancer therapy including chemotherapy, investigational agents or devices and immunotherapy within 4 weeks of the first dose of study medication * Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management * Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C * Inadequate bone marrow, liver and renal function * Inability to swallow oral medications or any condition that could affect the absorption of orally administered drugs * Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and CYP2C19 inhibitors/ inducers